The presentation and publication of the BRUIN CLL-314 trial followed the FDA’s December 3 decision to expand approval for ...

Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca ...

Eli Lilly (LLY) stock is in focus as its Jaypirca cancer drug succeeds in a Phase 3 trial for newly diagnosed patients with ...

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease ...

According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a ...

Jaypirca (pirtobrutinib) improved progression-free survival in treatment-naïve patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) when compared with bendamustine ...

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) innovation by showcasing the depth, ...

Jaypirca significantly improved progression-free survival in treatment-naive CLL/SLL, reducing disease progression or death risk by 80% compared to BR. The 24-month progression-free survival rate was ...

According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a ...

Zanubrutinib and venetoclax combination shows an 87% 36-month PFS rate in CLL/SLL patients, regardless of del (17p)/TP53 or IGHV status. The SEQUOIA trial demonstrates durable minimal residual disease ...

BEIJING, Dec. 09, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today ...

Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival ...